Oropharyngeal Candidiasis
📧 Sign up to get email alerts when something new happens for Oropharyngeal Candidiasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-01-14FDA Approved: FLUCONAZOLE IN SODIUM CHLORIDE — Supplemental Application (Hospira, Inc.)
The FDA approved Hospira's supplemental application for Fluconazole in Sodium Chloride (intravenous formulation), adding this generic IV flu…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Oropharyngeal Candidiasis (OPC) and S-ECC
A clinical trial update shows ongoing recruitment for studies on oropharyngeal candidiasis (oral thrush) and early childhood caries sponsore…
-
FDA approval · 2025-07-03FDA Approved: POSACONAZOLE — Supplemental Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved a supplemental application for posaconazole submitted by Glenmark Pharmaceuticals Inc., USA, under an ANDA.
-
FDA approval · 2025-04-25FDA Approved: FLUCONAZOLE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for fluconazole by Hikma Pharmaceuticals USA Inc., advancing the approval of this generic antifu…
-
FDA approval · 2025-03-21FDA Approved: NYSTATIN — Original Application (Aurobindo Pharma Limited)
FDA approved a generic Nystatin product from Aurobindo Pharma Limited under an Original Application.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-03-13FDA Approved: POSACONAZOLE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for posaconazole from Mylan Institutional LLC, updating the approval for the generic product.
-
EMA approval · 2025-01-21EMA Authorised: Posaconazole AHCL (posaconazole) — Accord Healthcare S.L.U.
EMA authorised Posaconazole AHCL by Accord Healthcare S.L.U. for mycoses. The EU marketing authorization was granted on 16 January 2025.
-
FDA approval · 2024-12-23FDA Approved: POSACONAZOLE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' posaconazole under an Original Application (ANDA), marking a generic approval for this antifungal.
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug [Phase 1]
Phase 1 study of Mycamine in children to evaluate safety and drug blood levels in fungal infections; the trial has completed.
-
FDA approval · 2024-10-25FDA Approved: NOXAFIL — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for NOXAFIL (posaconazole) from Merck Sharp & Dohme LLC.
-
FDA approval · 2024-10-24FDA Approved: POSACONAZOLE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for posaconazole (POSACONAZOLE), approving the generic product.
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis [Phase 1]
Phase 1 clinical trial update evaluating a nitric oxide releasing mouthwash (NORM) for the management of oropharyngeal candidiasis (oral can…
-
FDA approval · 2023-12-26FDA Approved: POSACONAZOLE — Original Application (Mylan Institutional LLC)
FDA approves a generic posaconazole product from Mylan Institutional LLC under an Original Application (ANDA 211500). The approval indicates…
-
FDA approval · 2023-10-24FDA Approved: FLUCONAZOLE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for fluconazole submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-08-28FDA Approved: POSACONAZOLE — Original Application (i3 Pharmaceuticals, LLC)
FDA approved an original application for posaconazole from i3 Pharmaceuticals, LLC (generic posaconazole).
-
FDA approval · 2023-07-14FDA Approved: FLUCONAZOLE — Supplemental Application (Baxter Healthcare Company)
FDA approved Baxter Healthcare Company's supplemental application for fluconazole (ANDA076766). This action confirms authorization of a gene…
-
FDA approval · 2023-03-17FDA Approved: FLUCONAZOLE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for fluconazole submitted by Rising Pharma Holdings, Inc., indicating approval of a generic formulat…
-
FDA approval · 2022-12-08FDA Approved: POSACONAZOLE — Original Application (NorthStar RxLLC)
The FDA approved NorthStar RxLLC's original application for posaconazole, granting authorization for a generic posaconazole product (ANDA 21…
-
FDA approval · 2022-07-28FDA Approved: POSACONAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for posaconazole delayed-release (POSACONAZOLE DELAYED-RELEASE) from Chartwell RX, LLC, updating its…
-
FDA approval · 2022-05-25FDA Approved: POSACONAZOLE — Original Application (Par Health USA, LLC)
FDA approved the original application for posaconazole (generic) by Par Health USA, LLC, marking the availability of a generic posaconazole …
-
FDA approval · 2022-02-04FDA Approved: POSACONAZOLE — Original Application (Biocon Phama Inc.)
FDA approved Biocon Phama Inc.'s original application for posaconazole, authorizing a generic formulation of the antifungal agent.
-
FDA approval · 2021-02-01FDA Approved: POSACONAZOLE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved the original application for posaconazole from Lupin Pharmaceuticals, enabling generic availability of the antifungal.
-
FDA approval · 2020-09-16FDA Approved: NOXAFIL — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved Merck's supplemental application for NOXAFIL (posaconazole), updating the product labeling with new indications/usage detai…
-
FDA approval · 2020-06-22FDA Approved: FLUCONAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for fluconazole submitted by Chartwell RX, LLC.
-
FDA approval · 2020-02-04FDA Approved: ORAVIG — Supplemental Application (Galt Pharmaceuticals, LLC)
The FDA approved a supplemental application for ORAVIG (miconazole) submitted by Galt Pharmaceuticals, LLC, signaling regulatory approval to…